ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
(Thomson Reuters ONE) -
SAN FRANCISCO, June 12, 2017 (GLOBE NEWSWIRE) -- In a late-breaking abstract at
the 77(th) American Diabetes Association meeting in San Diego, ProLynx LLC
announced a novel drug delivery system to support once-monthly subcutaneous (SC)
administration of a GLP-1 receptor agonist (GLP-1RA) called PLX039 for the
treatment of Type 2 diabetes (T2D). The work will be published in ACS Chemical
Biology.
GLP-1RAs have emerged as an important standard-of-care drug class for the
treatment of Type 2 diabetes and are projected to command a $12 Bill market by
2024. These agonists auto-regulate blood glucose concentration, have anti-
obesity effects, and may reduce risks for adverse cardiovascular events in
patients with T2D. Currently, there are three once- or twice- daily and three
once-weekly GLP-1RAs approved by the FDA; an additional once-weekly agonist and
a long-acting osmotic pump delivery system are in late stage trials. Yet, poor
medication adherence and persistence remain as major factors leading to failure
of glycemic control in almost 50% of T2D patients. Now, ProLynx has used its
half-life extension platform to develop a monthly-administered GLP-1RA. Compared
to weekly-administered agonists, obvious benefits are believed to include
greater patient convenience, compliance and persistence.
Daniel Santi, co-founder and President of ProLynx, said: "This is the first GLP-
1RA that does not require huge doses of a drug meant for weekly administration
to maintain therapeutic levels over a monthly period." Santi added: "PLX039
should find a dose-interval sweet-spot with its once-monthly administration.
Some patients will find that a once-weekly dosing interval is too short, and
will not want to have a long-acting osmotic pump implanted; for these patients,
the once monthly GLP-1 receptor agonist PLX039 should be just right."
In the ProLynx half-life extension platform, a drug is tethered to hydrogel
microspheres by a self-cleaving linker that is pre-programmed to release the
drug at a pre-determined rate. After SC injection, the drug is slowly released
from the microsphere depot into the systemic circulation. ProLynx attached their
peptidic GLP-1RA - a stabilized analog of exenatide - to its hydrogel
microspheres. After SC injection to rodents the GLP-1RA showed a serum half-life
of one month. Monthly injections of the formulation in diabetic rats showed
identical glucoregulatory effects as continuously infused exenatide, and
simulation of the pharmacokinetics indicate it should serve well as a once-a-
month treatment for T2D in humans.
About ProLynx. ProLynx LLC is a privately held biotechnology company developing
proprietary drug delivery systems for half-life extension of proteins, peptides
and small molecules. The company is seeking to apply its technology to extend
half-lives of drug candidates of pharmaceutical companies, and to improve
properties of off-patent therapeutics. ProLynx has a monthly GLP-1 receptor
agonist and a subcutaneous long-acting octreotide in its pre-clinical portfolio,
and a PEG~SN-38 in Phase 1 clinical trials. The company is located in San
Francisco, CA. Further information about the company may be found at
www.ProLynxllc.com.
Contact:
Eric Schneider: Eric(at)ProLynxllc.com
Or BD(at)ProLynxllc.com
415-552-5306
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProLynx LLC via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.06.2017 - 15:00 Uhr
Sprache: Deutsch
News-ID 547410
Anzahl Zeichen: 4195
contact information:
Town:
San Francisco
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 317 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist"
steht unter der journalistisch-redaktionellen Verantwortung von
ProLynx LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
